🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  2. 2wIPV+1sIPV

    Biotech Pharmaceutical Co.,

    Poliomyelitis

    approved mab active

    1 trial

  3. 2wIPV+1sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    approved mab active

    1 trial

  4. ADALIMUMAB, BARICITINIB, BARICITINIB, ADALIMUMAB, ETANERCEPT

    Eli Lilly Co.

    Rheumatoid Arthritis

    approved small molecule active

    1 trial

  5. Abemaciclib

    Eli Lilly and Company

    Metastatic Breast Cancer

    approved small molecule terminated

    1 trial

  6. Abemaciclib

    Eli Lilly and Company

    Breast Neoplasms

    approved small molecule completed

    1 trial

  7. Aflibercept

    Regeneron UK Limited

    Fibrovascular Pigment Epithelial Detachment

    approved small molecule terminated

    1 trial

  8. Aflibercept

    Regeneron UK Limited

    Submacular Vascularized Pigment Epithelial Detachments

    approved small molecule completed

    1 trial

  9. Anagrelide

    Takeda

    Thrombocythemia, Hemorrhagic

    approved small molecule completed

    1 trial

  10. BILINDA GYNIAL 0,03 mg/2 mg Filmtabletten, Selina Gynial 0,03 mg/0,15 mg Filmtabletten

    Pari Pharma GmbH

    Hormonal contraception

    approved small molecule active

    1 trial

  11. Bavencio 20 mg/mL concentrate for solution for infusion

    Disc Medicine

    urothelial cancer, Bladder cancer, muscle invasive bladder cancer

    approved small molecule active

    1 trial

  12. Bismuth-based susceptibility-guided treatment

    Hospital Authority, Hong Kong

    Helicobacter Pylori

    approved small molecule completed

    1 trial

  13. Camrelizumab + chemotherapy+Thalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    approved small molecule active

    1 trial

  14. CareLink Remote Monitoring

    Rhythm Pharmaceuticals Netherlands B.V.

    Pacemaker

    approved other completed

    1 trial

  15. Cetrorelix Acetate

    United Therapeutics Europe Ltd

    Infertility

    approved small molecule active

    1 trial

  16. Ciprofol

    The First People's Hospital of Lianyungang

    Postoperative Delirium (POD)

    approved small molecule active

    1 trial

  17. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Delirium After Living Donor Renal Transplantation

    approved small molecule active

    1 trial

  18. Eliquis 5 mg film-coated tablets, Waran 2,5 mg tabletter, OPTISON 0.19 mg/ml dispersion for injection, SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, Eliquis 2.5 mg film-coated tablets

    The George Institute

    Left ventricular thrombosis., Acute mycocardial infarction (AMI)

    approved small molecule active

    1 trial

  19. Esketamine 0.2 mg/kg

    The First People's Hospital of Lianyungang

    Cesarean Delivery

    approved small molecule completed

    1 trial

  20. GEMCITABINE HYDROCHLORIDE, CISPLATIN, AVELUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE

    Fondazione Telethon ETS

    metastatic or locally advanced urothelial cancer

    approved small molecule active

    1 trial

  21. HALOPERIDOL, CLOZAPINE, TIAPRIDE, SERTINDOLE, PALIPERIDONE, OLANZAPINE, SULPIRIDE, ARIPIPRAZOLE, LURASIDONE, RISPERIDONE, AMISULPRIDE, CHLORPROMAZINE, PIMOZIDE, QUETIAPINE

    Disc Medicine

    HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.

    approved small molecule active

    1 trial

  22. Heliox inspirate

    United Therapeutics Europe Ltd

    Work of Breathing

    approved small molecule active

    1 trial

  23. Hiconcil 500 mg trde kapsule, Enterol 250 mg, gélules, Matched Placebo will consist in caspules similar to the 250 mg capsules of the Saccharomyces boulardii CNCM-I-745 but with no active ingredient

    Biocodex

    Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))

    approved small molecule active

    1 trial

  24. Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources